Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp63551_8k.htm |
| EX-99.1 - EXHBIIT 99.1 - Shire plc | dp63551_ex9901.htm |
| EX-99.7 - EXHBITI 99.7 - Shire plc | dp63551_ex9907.htm |
| EX-99.8 - EXHIBIT 99.8 - Shire plc | dp63551_ex9908.htm |
| EX-99.4 - EXHIBIT 99.4 - Shire plc | dp63551_ex9904.htm |
| EX-99.5 - EXHBIIT 99.5 - Shire plc | dp63551_ex9905.htm |
| EX-99.6 - EXHIBIT 99.6 - Shire plc | dp63551_ex9906.htm |
| EX-99.3 - EXHIBIT 99.3 - Shire plc | dp63551_ex9903.htm |
Exhibit 99.2
|
Press Release www.shire.com |
 |
Director/PDMR Shareholding
February 15, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified today that Flemming Ornskov, Chief Executive Officer of the Company, acquired 1,300 American Depositary Shares (“ADSs”) at an average price of $154.12 per ADS. The transaction took place on the NASDAQ Global Select Market on February 12, 2016. One ADS is equal to three Ordinary Shares of 5 pence each in the Company.
This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Matthew Osborne | mattosborne@shire.com | +1 781 482 9502 |
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX